The ICORN Treatment registry is a prospective, observational study established to assess and record treatment outcomes from emerging HCV therapeutics using data from real-life clinical practice. Ethical approval for the study was obtained from the St. James’s Hospital/Tallaght Research Ethics Committee.
a) The effectiveness of HCV protease inhibitors in the real world setting
b) The cost of treating patients with HCV triple therapy treatment paradigms including drug costs and costs associated with management of side effects and additional resource utilisation costs
c) Absolute risk of adverse events in HCV treated patients and the potential to identify emergent ADRs
d) To assess host factors that may influence HCV treatment outcomes or tolerability
1.2.1 Patient Eligibility
Patients with Genotype 1 HCV prescribed triple therapy with a protease inhibitor, either telaprevir or boceprevir, are recruited by clinicians or clinical nurse specialists in the seven designated sites.